Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.
Although critical for initiating and regulating immune responses, the therapeutic use of individual cytokines as anticancer immunotherapeutic agents has achieved only modest clinical success. Consequently, many current strategies have focused on the use of specific immunotherapeutic agonists that engage individual receptors of innate immune networks, such as the Toll-like receptor (TLR) system, each resulting in specific patterns of gene expression, cytokine production, and inflammatory outcome. However, these immunotherapeutics are constrained by variable cellular TLR expression and responsiveness to particular TLR agonists, as well as the specific cellular context of different tumors. We hypothesized that overexpression of MyD88, a pivotal regulator of multiple TLR signaling pathways, could circumvent these constraints and mimic coordinated TLR signaling across all cell types in a ligand-independent fashion. To explore this hypothesis, we generated an adenoviral vector expressing MyD88 and show that Ad-MyD88 infection elicits extensive Th1-specific transcriptional and secreted cytokine signatures in all murine and human cell types tested in vitro and in vivo. Importantly, in vivo intratumoral injection of Ad-MyD88 into established tumor masses enhanced adaptive immune responses and inhibited local tumor immunosuppression, resulting in significantly inhibited local and systemic growth of multiple tumor types. Finally, Ad-MyD88 infection of primary human dendritic cells, tumor-associated fibroblasts, and colorectal carcinoma cells elicited significant Th1-type cytokine responses, resulting in enhanced tumor cell lysis and expansion of human tumor antigen-specific T cells. Thus, Ad-MyD88 initiated robust antitumor activity in established murine tumor microenvironments and in human contexts, suggesting its potential effectiveness as a clinical immunotherapeutic strategy.
Hartman
Zachary C
ZC
Department of Surgery and Comprehensive Cancer Center and Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Osada
Takuya
T
Glass
Oliver
O
Yang
Xiao Y
XY
Lei
Gang-Jun
GJ
Lyerly
H Kim
HK
Clay
Timothy M
TM
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000276:immunology; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D053594:Myeloid Differentiation Factor 88 / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology; D051193:Toll-Like Receptors / Q000276:immunology* / Q000378:metabolism
D018984:Epitopes, T-Lymphocyte; D008024:Ligands; C507779:MYD88 protein, human; C507780:Myd88 protein, mouse; D053594:Myeloid Differentiation Factor 88; D051193:Toll-Like Receptors
Cancer Res. 2005 Jun 15;65(12):5009-14
15958541
FEBS Lett. 2007 Jul 10;581(17):3223-9
17583698
J Immunother. 2005 Jan-Feb;28(1):63-72
15614046
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42
17108085
Cancer Res. 2003 Oct 1;63(19):6478-87
14559840
Nat Med. 2007 May;13(5):552-9
17479101
N Engl J Med. 1992 Jul 2;327(1):28-35
1375975
Expert Opin Biol Ther. 2007 Aug;7(8):1257-66
17696823
J Immunol. 2007 Aug 1;179(3):1960-8
17641063
Ann Surg Oncol. 2006 Jan;13(1):118-24
16372153
Adv Drug Deliv Rev. 2006 Oct 1;58(8):902-15
16979786
J Clin Oncol. 2001 Aug 1;19(15):3477-82
11481353
J Biol Chem. 1998 May 15;273(20):12203-9
9575168
J Virol. 2007 Feb;81(4):1796-812
17121790
Curr Opin Immunol. 2006 Feb;18(1):3-9
16343886
Curr Opin Immunol. 2006 Apr;18(2):226-31
16459066
J Virol. 2006 Jul;80(13):6218-24
16775309
Cancer Res. 1998 Apr 1;58(7):1486-93
9537252
Blood. 1997 Oct 1;90(7):2541-8
9326219
Annu Rev Immunol. 1999;17:189-220
10358757
Virology. 2007 Feb 20;358(2):357-72
17027060
Nat Protoc. 2009;4(1):44-57
19131956
Nat Rev Immunol. 2007 May;7(5):353-64
17457343
Mol Cancer Ther. 2005 Nov;4(11):1645-52
16275985
Nat Rev Cancer. 2009 Jan;9(1):57-63
19052556
Science. 2004 Jul 9;305(5681):200-5
15247469
Nat Immunol. 2005 Aug;6(8):769-76
15995707
Curr Opin Genet Dev. 2005 Feb;15(1):97-101
15661539
Pharmacol Rev. 2009 Jun;61(2):177-97
19474110
J Endotoxin Res. 2005;11(4):220-4
16176658
Clin Cancer Res. 1997 Mar;3(3):409-17
9815699
Nat Rev Cancer. 2004 Jan;4(1):11-22
14708024
Cell. 2006 Feb 24;124(4):783-801
16497588
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486-90
2137615
Immunol Rev. 2005 Feb;203:10-20
15661018
Lancet. 1988 Mar 26;1(8587):667-72
2895212
Nat Biotechnol. 2009 Feb;27(2):129-39
19204689
Gene Ther. 2001 Feb;8(4):259-67
11313799
Methods. 2001 Dec;25(4):402-8
11846609
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14
9482916
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.1
18432774
Clin Cancer Res. 2001 Nov;7(11):3625-8
11705885
J Clin Invest. 2000 Apr;105(7):985-93
10749577
Adv Immunol. 2006;90:51-81
16730261
Mol Ther. 2005 Jul;12(1):18-27
15963916
Mol Cell. 1998 Aug;2(2):253-8
9734363
Oncogene. 2008 Jan 7;27(2):218-24
18176603
Nat Rev Cancer. 2009 May;9(5):361-71
19343034
Immunol Rev. 2009 Jan;227(1):221-33
19120487
J Clin Invest. 2008 Jun;118(6):1991-2001
18523649